SkinStylus Receives US FDA Clearance for the Improvement of Periorbital Wrinkles in All Skin Types

The US Food and Drug Administration (FDA) has cleared SkinHealth Systems Inc’s SkinStylus microneedling device for the improvement of the appearance of periorbital wrinkles in adults aged 22 years and older for all Fitzpatrick skin types.

Categorized by the FDA as a Class II Medical Device, the SkinStylus SteriLock MicroSystem is FDA-cleared for the following indications in adults aged 22 years and older:

  • Improvement in the appearance of periorbital wrinkles in Fitzpatrick skin types I–VI, inclusive of the delicate skin around the eyes, including crow’s feet
  • Improvement in the appearance of facial acne scars in Fitzpatrick skin types I, II, and III
  • Improvement in the appearance of surgical or traumatic hypertrophic scars on the abdomen

“Based on my experience as a principal investigator in the clinical study, SkinStylus demonstrated statistically and clinically meaningful improvements in periorbital wrinkles across all Fitzpatrick skin types, which is a notable advancement in microneedling technology,” says Glynis Ablon, MD, FAAD, a Manhattan Beach, CA-based Dermatologist, in a news release. “The device’s multiple FDA-cleared indications further support its versatility in clinical practice. In my experience, patients felt it was a more comfortable procedure compared to other microneedling systems, and I found it much easier to handle as a user, contributing to an improved overall treatment.”

The clinical data supporting the new indication was recently presented at the 2026 SCALE Annual Meeting.

“Achieving FDA clearance for the improvement of periorbital wrinkles marks an important milestone for SkinStylus and for SkinHealth Systems,” adds Whitney Cypes, Chief Brand and Clinical Innovation Officer of SkinHealth Systems. “As microneedling continues to grow rapidly within medical aesthetics, we are building on SkinStylus’s clinical strength because we believe in its long-term role in our ecosystem. Expanding our FDA-cleared indications better positions us to compete in the microneedling category and reinforces our strategy to build a differentiated, science-backed platform that delivers meaningful, visible results for providers and consumers.”